Access to this item is restricted for 12 months after publication by request of the publisher.. Restriction lift date: 2018-10-14
CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor
Loading...
Files
Accepted Version
Date
2017-10-14
Authors
Ronan, Nicola J.
Einarsson, Gisli G.
Twomey, Maria
Mooney, Denver
Mullane, David
NiChroinin, Muireann
O'Callaghan, Grace
Shanahan, Fergus
Murphy, Desmond M.
O'Connor, Owen J.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Inc. on behalf of the American College of Chest Physicians
Published Version
Abstract
Background: Ivacaftor produces significant clinical benefit in patients with cystic fibrosis (CF) with the G551D mutation. Prevalence of this mutation at the Cork CF Centre is 23%. This study assessed the impact of CFTR modulation on multiple modalities of patient assessment. Methods: Thirty-three patients with the G551D mutation were assessed at baseline and prospectively every 3 months for 1 year after initiation of ivacaftor. Change in ultra-low-dose chest CT scans, blood inflammatory mediators, and the sputum microbiome were assessed. Results: Significant improvements in FEV1, BMI, and sweat chloride levels were observed post-ivacaftor treatment. Improvement in ultra-low-dose CT imaging scores were observed after treatment, with significant mean reductions in total Bhalla score (P < .01), peribronchial thickening (P = .035), and extent of mucous plugging (P < .001). Reductions in circulating inflammatory markers, including interleukin (IL)-1β, IL-6, and IL-8 were demonstrated. There was a 30% reduction in the relative abundance of Pseudomonas species and an increase in the relative abundance of bacteria associated with more stable community structures. Posttreatment community richness increased significantly (P = .03). Conclusions: Early and sustained improvements on ultra-low-dose CT scores suggest it may be a useful method of evaluating treatment response. It paralleled improvement in symptoms, circulating inflammatory markers, and changes in the lung microbiota.
Description
Keywords
Cystic fibrosis , Ivacaftor , G551D , Low-dose chest CT imaging
Citation
Ronan, N. J., Einarsson, G. G., Twomey, M., Mooney, D., Mullane, D., NiChroinin, M., O’Callaghan, G., Shanahan, F., Murphy, D. M., O’Connor, O. J., Shortt, C. A., Tunney, M. M., Eustace, J. A., Maher, M. M., Elborn, J. S. and Plant, B. J. (2017) ‘CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor’, Chest, 153(2), pp. 395-403. doi: 10.1016/j.chest.2017.10.005.